No Data
No Data
Inventiva Phase 2 Study for MASH Drug Meets Primary Endpoint
Madrigal Climbs Amid Hopes for New NASH Drug; B. Riley Upgrades
Madrigal and Liver Drug Developers Fall Ahead of FDA Decision on NASH Therapy
Liver Drug Developers Outperform as U.S. Awaits First NASH Drug
Enanta Pharmaceuticals Shareholders Affirm Management Direction
Enanta Pharmaceuticals to Participate at Leerink Partners Global Biopharma Conference
PDF Version WATERTOWN, Mass.--(BUSINESS WIRE)--Mar. 6, 2024-- Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for indica
No Data